check_circleStudy Completed

gastrointestinal stromal tumors

Regorafenib in subjects with gastrointestinal stromal tumors (GIST) who have progressed after standard therapy (Managed Access Program)

Trial purpose

The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.

Key Participants Requirements

Sex

Both

Age

18 - 99 Years

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteer
N/A

Trial design

Guidelines for treatment with regorafenib in patients with gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib and sunitinib (Managed Access Program)
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A